Company Performance Metrics
Chris Christoffersen: President and CEOPast Role: Morgenthaler Ventures, Partner
Ribozyme Pharmaceuticals is a biotechnology company. It develops therapeutics based on RNA interference (RNAi) technology.
The company provides research, preclinical, and clinical development services with product candidates in various areas including age-related macular degeneration (AMD), chronic hepatitis, dermatology, asthma, Huntington’s
disease (HD), oncology, and diabetes. It offers Sirna-027, which completed phase I clinical trial and is used for the treatment of AMD; Sirna-034, which is under preclinical stage and is used for the treatment of hepatitis C virus; and various drugs under preclinical stage of development for asthma, HD, chronic hepatitis, diabetes, and dermatology.
The company has strategic alliances with Allergan, Inc., Eli Lilly and Company, Targeted Genetics, Protiva, Archemix Corporation, and GlaxoSmithKline.
Ribozyme Pharmaceuticals was founded in 1992 and is headquartered in San Francisco, California. As of March 5, 2014, it operates as a subsidiary of Alnylam Pharmaceuticals.
